Novartis journeys to Mecca for Saudi vax effort

A Swiss-Saudi partnership has resulted in the opening of a vaccine plant in the holy city of Mecca. Novartis ($NVS) will provide vaccine manufacturing know-how to Arab Company for Pharmaceutical Products (Arabio), which owns the plant. Initial capacity will be 16 million doses per year when operation begins early next year, rising to 35 million vaccines. There's irony in the plant's location: vax-conscious Saudis request that haj pilgrims carry a certificate proving they've been vaccinated. Article

Suggested Articles

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.

Boehringer Ingelheim is investing $50 million in an animal health plant in Puerto Rico, adding 105 jobs.

Teva will begin producing chemo drug vincristine in the U.S. but has resisted the idea that its withdrawal from the market led to a shortage.